Evidence map›Paper›PMID 38252831›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Viruses traverse the human proteome through peptide interfaces that can be biomimetically leveraged for drug discovery.

Laurène Meyniel-Schicklin, Jérôme Amaudrut, Pierre Mallinjoud, Fabrice Guillier, Philippe E Mangeot, Laetitia Lines, Anne Aublin-Gex, Caroline Scholtes, Claire Punginelli, Stéphane Joly and 19 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Uncovering cancer dependencies in peptide-interacting protein pockets.bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 4 institutions in 2 countries.

Laurène Meyniel-SchicklinENYO Pharma, Lyon 69008, France.ORCID 0009-0007-5730-1102
Jérôme AmaudrutInventiva, Daix 21121, France.ORCID 0000-0003-0498-4089
Pierre MallinjoudENYO Pharma, Lyon 69008, France.ORCID 0009-0008-6146-1595
Fabrice GuillierInventiva, Daix 21121, France.
Philippe E MangeotCentre International de Recherche en Infectiologie, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon 69007, France.
Laetitia LinesENYO Pharma, Lyon 69008, France.ORCID 0009-0004-2597-9267
Anne Aublin-GexCentre International de Recherche en Infectiologie, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon 69007, France.ORCID 0000-0002-7601-4965
Caroline ScholtesCentre International de Recherche en Infectiologie, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon 69007, France.ORCID 0000-0003-0691-8480
Claire PunginelliCentre International de Recherche en Infectiologie, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon 69007, France.
Stéphane JolyENYO Pharma, Lyon 69008, France.
Florence VasseurUniversité de Paris, INSERM U1151, CNRS UMR 8253, Institut Necker Enfants Malades, Département "Croissance et Signalisation", Paris 75015, France.
Evelyne ManetCentre International de Recherche en Infectiologie, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon 69007, France.
Henri GruffatCentre International de Recherche en Infectiologie, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon 69007, France.ORCID 0000-0002-4735-6894
Thomas HenryCentre International de Recherche en Infectiologie, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon 69007, France.ORCID 0000-0002-0687-8565
Farès HalitimENYO Pharma, Lyon 69008, France.
Jean-Laurent PaparinENYO Pharma, Lyon 69008, France.
Peter MachinENYO Pharma, Lyon 69008, France.
Raphaël DarteilENYO Pharma, Lyon 69008, France.
Diane SampsonENYO Pharma, Lyon 69008, France.
Ivan MikaelianUniversité de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon 69373, France.ORCID 0000-0001-5222-3570
Lydie LaneComputer and Laboratory Investigation of Proteins of Human Origin Group, Swiss Institute of Bioinformatics, Lausanne 1015, Switzerland.
Vincent NavratilPôle Rhône-Alpes de bioinformatique, Rhône-Alpes Bioinformatics Center, Université Lyon 1, Villeurbanne 69622, France.ORCID 0000-0001-9974-1877
Marie-Pierre Golinelli-CohenUniversité Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, Unité Propre de Recherche 2301, Gif-sur-Yvette 91198, France.
Fabiola TerziUniversité de Paris, INSERM U1151, CNRS UMR 8253, Institut Necker Enfants Malades, Département "Croissance et Signalisation", Paris 75015, France.
Patrice AndréCentre International de Recherche en Infectiologie, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon 69007, France.ORCID 0000-0002-5834-7395
Vincent LotteauCentre International de Recherche en Infectiologie, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon 69007, France.ORCID 0000-0003-0997-3282
Jacky VonderscherENYO Pharma, Lyon 69008, France.
Eric C MeldrumENYO Pharma, Lyon 69008, France.
Benoit de ChasseyENYO Pharma, Lyon 69008, France.ORCID 0000-0002-7488-8597
Université Claude Bernard Lyon 1 · FRCentre National de la Recherche Scientifique · FRInventiva (France) · FRSIB Swiss Institute of Bioinformatics · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a drug design strategy based on structural knowledge of protein-protein interfaces selected through virus-host coevolution and translated into highly potential small molecules. This approach is grounded on Vinland, the most comprehensive atlas of virus-human protein-protein interactions with annotation of interacting domains. From this inspiration, we identified small viral protein domains responsible for interaction with human proteins. These peptides form a library of new chemical entities used to screen for replication modulators of several pathogens. As a proof of concept, a peptide from a KSHV protein, identified as an inhibitor of influenza virus replication, was translated into a small molecule series with low nanomolar antiviral activity. By targeting the NEET proteins, these molecules turn out to be of therapeutic interest in a nonalcoholic steatohepatitis mouse model with kidney lesions. This study provides a biomimetic framework to design original chemistries targeting cellular proteins, with indications going far beyond infectious diseases.

Indexed as

Influenza, HumanVirusesAnimalsDrug DiscoveryHumansMicePeptidesProteomePeptidesProteomebiomimetismchemoinformaticsinteractomicskidneyviruses

Identifiers

PMID38252831
PMCPMC10835127
OpenAlexW4391091903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.